AB Science S.A. (ABSCF)
OTCMKTS · Delayed Price · Currency is USD
1.450
+0.180 (14.17%)
At close: Dec 22, 2025
AB Science Employees
AB Science had 36 employees as of June 30, 2025. The number of employees decreased by 3 or -7.69% since the number was reported on December 31, 2024.
Employees
36
Change
-3
Growth
-7.69%
Revenue / Employee
$33,503
Profits / Employee
-$278,561
Market Cap
115.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 36 | -3 | -7.69% | 36 | 0 |
| Dec 31, 2024 | 39 | -18 | -31.58% | 28 | 11 |
| Dec 31, 2023 | 57 | -46 | -44.66% | 51 | 6 |
| Dec 31, 2022 | 103 | 5 | 5.10% | 103 | 0 |
| Dec 31, 2021 | 98 | 6 | 6.52% | 98 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jushi Holdings | 1,234 |
| MariMed | 832 |
| Earth Science Tech | 76 |
| Elite Pharmaceuticals | 68 |
| Radnostix | 42 |
| Healthy Extracts | 2 |
AB Science News
- 3 days ago - AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors - GlobeNewsWire
- 22 days ago - AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 - GlobeNewsWire
- 5 weeks ago - AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia - GlobeNewsWire
- 7 weeks ago - AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040 - GlobeNewsWire
- 2 months ago - AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share - GlobeNewsWire
- 2 months ago - AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers - GlobeNewsWire
- 2 months ago - AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function - GlobeNewsWire
- 4 months ago - AB Science announces the successful completion of a EUR 2.8 million private placement - GlobeNewsWire